Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAF with or without HBIG to prevent HBV reinfection after liver transplantation
ChiCTR2200062235Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tenofovir alafenamide in hepatitis B (HBV) (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Hepatitis B surface antigen. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
tenofovir alafenamide
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on ChiCTR2200062235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062235.